Verona Pharma plc
Verona Pharma plc (VRNA) Stock Competitors & Peer Comparison
See (VRNA) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VRNA | $105.09 | -0.05% | 8.9B | -52.54 | -$2.00 | N/A |
| VRTX | $456.87 | -2.62% | 117.3B | -120.23 | -$3.80 | N/A |
| REGN | $545.46 | -1.64% | 57.9B | 13.87 | $39.32 | +0.32% |
| ALNY | $392.24 | +15.43% | 51.1B | -185.90 | -$2.11 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ARGX | $670.33 | +11.93% | 41B | 40.80 | $16.41 | N/A |
| BNTX | $107.50 | -2.32% | 25.8B | -28.67 | -$3.75 | N/A |
| RPRX | $36.80 | -0.86% | 20.7B | 15.02 | $2.45 | +2.32% |
| BGNE | $184.71 | +0.49% | 20.2B | -22.55 | -$8.19 | N/A |
| SMMT | $26.37 | -1.09% | 19.6B | -77.56 | -$0.34 | N/A |
Stock Comparison
VRNA vs VRTX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, VRTX has a market cap of 117.3B. Regarding current trading prices, VRNA is priced at $105.09, while VRTX trades at $456.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas VRTX's P/E ratio is -120.23. In terms of profitability, VRNA's ROE is -0.90%, compared to VRTX's ROE of -0.06%. Regarding short-term risk, VRNA is less volatile compared to VRTX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check VRTX's competition here
VRNA vs REGN Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, REGN has a market cap of 57.9B. Regarding current trading prices, VRNA is priced at $105.09, while REGN trades at $545.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas REGN's P/E ratio is 13.87. In terms of profitability, VRNA's ROE is -0.90%, compared to REGN's ROE of +0.15%. Regarding short-term risk, VRNA is less volatile compared to REGN. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check REGN's competition here
VRNA vs ALNY Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ALNY has a market cap of 51.1B. Regarding current trading prices, VRNA is priced at $105.09, while ALNY trades at $392.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ALNY's P/E ratio is -185.90. In terms of profitability, VRNA's ROE is -0.90%, compared to ALNY's ROE of -5.09%. Regarding short-term risk, VRNA is less volatile compared to ALNY. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check ALNY's competition here
VRNA vs SGEN Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VRNA is priced at $105.09, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VRNA's ROE is -0.90%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VRNA is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check SGEN's competition here
VRNA vs ARGX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ARGX has a market cap of 41B. Regarding current trading prices, VRNA is priced at $105.09, while ARGX trades at $670.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ARGX's P/E ratio is 40.80. In terms of profitability, VRNA's ROE is -0.90%, compared to ARGX's ROE of +0.23%. Regarding short-term risk, VRNA is less volatile compared to ARGX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check ARGX's competition here
VRNA vs BNTX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, BNTX has a market cap of 25.8B. Regarding current trading prices, VRNA is priced at $105.09, while BNTX trades at $107.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas BNTX's P/E ratio is -28.67. In terms of profitability, VRNA's ROE is -0.90%, compared to BNTX's ROE of -0.04%. Regarding short-term risk, VRNA is less volatile compared to BNTX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check BNTX's competition here
VRNA vs RPRX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RPRX has a market cap of 20.7B. Regarding current trading prices, VRNA is priced at $105.09, while RPRX trades at $36.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas RPRX's P/E ratio is 15.02. In terms of profitability, VRNA's ROE is -0.90%, compared to RPRX's ROE of +0.16%. Regarding short-term risk, VRNA is less volatile compared to RPRX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check RPRX's competition here
VRNA vs BGNE Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VRNA is priced at $105.09, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VRNA's ROE is -0.90%, compared to BGNE's ROE of -0.12%. Regarding short-term risk, VRNA is less volatile compared to BGNE. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check BGNE's competition here
VRNA vs SMMT Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, SMMT has a market cap of 19.6B. Regarding current trading prices, VRNA is priced at $105.09, while SMMT trades at $26.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas SMMT's P/E ratio is -77.56. In terms of profitability, VRNA's ROE is -0.90%, compared to SMMT's ROE of -0.70%. Regarding short-term risk, VRNA is less volatile compared to SMMT. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check SMMT's competition here
VRNA vs DNA-WT Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VRNA is priced at $105.09, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VRNA's ROE is -0.90%, compared to DNA-WT's ROE of -0.63%. Regarding short-term risk, VRNA is less volatile compared to DNA-WT. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check DNA-WT's competition here
VRNA vs INCY Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, INCY has a market cap of 14.6B. Regarding current trading prices, VRNA is priced at $105.09, while INCY trades at $74.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas INCY's P/E ratio is 17.70. In terms of profitability, VRNA's ROE is -0.90%, compared to INCY's ROE of +0.34%. Regarding short-term risk, VRNA is less volatile compared to INCY. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check INCY's competition here
VRNA vs GMAB Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, GMAB has a market cap of 13.4B. Regarding current trading prices, VRNA is priced at $105.09, while GMAB trades at $21.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas GMAB's P/E ratio is 12.75. In terms of profitability, VRNA's ROE is -0.90%, compared to GMAB's ROE of +0.26%. Regarding short-term risk, VRNA is less volatile compared to GMAB. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check GMAB's competition here
VRNA vs KRTX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VRNA is priced at $105.09, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VRNA's ROE is -0.90%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VRNA is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check KRTX's competition here
VRNA vs UTHR Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, UTHR has a market cap of 12.4B. Regarding current trading prices, VRNA is priced at $105.09, while UTHR trades at $274.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas UTHR's P/E ratio is 10.94. In terms of profitability, VRNA's ROE is -0.90%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, VRNA is less volatile compared to UTHR. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check UTHR's competition here
VRNA vs MRNA Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MRNA has a market cap of 11.4B. Regarding current trading prices, VRNA is priced at $105.09, while MRNA trades at $29.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas MRNA's P/E ratio is -3.39. In terms of profitability, VRNA's ROE is -0.90%, compared to MRNA's ROE of -0.30%. Regarding short-term risk, VRNA is less volatile compared to MRNA. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check MRNA's competition here
VRNA vs BMRN Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, BMRN has a market cap of 11.1B. Regarding current trading prices, VRNA is priced at $105.09, while BMRN trades at $57.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas BMRN's P/E ratio is 21.44. In terms of profitability, VRNA's ROE is -0.90%, compared to BMRN's ROE of +0.09%. Regarding short-term risk, VRNA is less volatile compared to BMRN. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check BMRN's competition here
VRNA vs ASND Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ASND has a market cap of 10.5B. Regarding current trading prices, VRNA is priced at $105.09, while ASND trades at $173.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ASND's P/E ratio is -25.40. In terms of profitability, VRNA's ROE is -0.90%, compared to ASND's ROE of +1.91%. Regarding short-term risk, VRNA is less volatile compared to ASND. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check ASND's competition here
VRNA vs EXEL Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, EXEL has a market cap of 9.8B. Regarding current trading prices, VRNA is priced at $105.09, while EXEL trades at $36.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas EXEL's P/E ratio is 17.41. In terms of profitability, VRNA's ROE is -0.90%, compared to EXEL's ROE of +0.28%. Regarding short-term risk, VRNA is less volatile compared to EXEL. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check EXEL's competition here
VRNA vs RXDX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VRNA is priced at $105.09, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VRNA's ROE is -0.90%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VRNA is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check RXDX's competition here
VRNA vs BBIO Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, BBIO has a market cap of 9B. Regarding current trading prices, VRNA is priced at $105.09, while BBIO trades at $47.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas BBIO's P/E ratio is -13.28. In terms of profitability, VRNA's ROE is -0.90%, compared to BBIO's ROE of +0.49%. Regarding short-term risk, VRNA is less volatile compared to BBIO. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check BBIO's competition here
VRNA vs IMGN Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VRNA is priced at $105.09, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VRNA's ROE is -0.90%, compared to IMGN's ROE of -1.43%. Regarding short-term risk, VRNA is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check IMGN's competition here
VRNA vs TECH Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, TECH has a market cap of 8.6B. Regarding current trading prices, VRNA is priced at $105.09, while TECH trades at $54.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas TECH's P/E ratio is 65.94. In terms of profitability, VRNA's ROE is -0.90%, compared to TECH's ROE of +0.06%. Regarding short-term risk, VRNA is less volatile compared to TECH. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check TECH's competition here
VRNA vs BPMC Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VRNA is priced at $105.09, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas BPMC's P/E ratio is -51.58. In terms of profitability, VRNA's ROE is -0.90%, compared to BPMC's ROE of -0.49%. Regarding short-term risk, VRNA is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check BPMC's competition here
VRNA vs CERE Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VRNA is priced at $105.09, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas CERE's P/E ratio is -16.47. In terms of profitability, VRNA's ROE is -0.90%, compared to CERE's ROE of -0.43%. Regarding short-term risk, VRNA is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check CERE's competition here
VRNA vs ROIVW Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ROIVW has a market cap of 7.8B. Regarding current trading prices, VRNA is priced at $105.09, while ROIVW trades at $2.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ROIVW's P/E ratio is -0.67. In terms of profitability, VRNA's ROE is -0.90%, compared to ROIVW's ROE of -0.03%. Regarding short-term risk, VRNA is less volatile compared to ROIVW. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check ROIVW's competition here
VRNA vs ROIV Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ROIV has a market cap of 7.7B. Regarding current trading prices, VRNA is priced at $105.09, while ROIV trades at $11.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ROIV's P/E ratio is -15.15. In terms of profitability, VRNA's ROE is -0.90%, compared to ROIV's ROE of -0.03%. Regarding short-term risk, VRNA is less volatile compared to ROIV. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check ROIV's competition here
VRNA vs HALO Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, HALO has a market cap of 7.4B. Regarding current trading prices, VRNA is priced at $105.09, while HALO trades at $59.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas HALO's P/E ratio is 15.95. In terms of profitability, VRNA's ROE is -0.90%, compared to HALO's ROE of +1.22%. Regarding short-term risk, VRNA is less volatile compared to HALO. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check HALO's competition here
VRNA vs CORT Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CORT has a market cap of 7.1B. Regarding current trading prices, VRNA is priced at $105.09, while CORT trades at $67.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas CORT's P/E ratio is 58.41. In terms of profitability, VRNA's ROE is -0.90%, compared to CORT's ROE of +0.20%. Regarding short-term risk, VRNA is less volatile compared to CORT. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check CORT's competition here
VRNA vs RVMD Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RVMD has a market cap of 6.9B. Regarding current trading prices, VRNA is priced at $105.09, while RVMD trades at $37.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas RVMD's P/E ratio is -9.29. In terms of profitability, VRNA's ROE is -0.90%, compared to RVMD's ROE of -0.37%. Regarding short-term risk, VRNA is less volatile compared to RVMD. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check RVMD's competition here
VRNA vs JAZZ Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, JAZZ has a market cap of 6.9B. Regarding current trading prices, VRNA is priced at $105.09, while JAZZ trades at $114.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas JAZZ's P/E ratio is 15.57. In terms of profitability, VRNA's ROE is -0.90%, compared to JAZZ's ROE of +0.12%. Regarding short-term risk, VRNA is less volatile compared to JAZZ. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check JAZZ's competition here
VRNA vs IONS Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, IONS has a market cap of 6.8B. Regarding current trading prices, VRNA is priced at $105.09, while IONS trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas IONS's P/E ratio is -24.42. In terms of profitability, VRNA's ROE is -0.90%, compared to IONS's ROE of -0.45%. Regarding short-term risk, VRNA is less volatile compared to IONS. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check IONS's competition here
VRNA vs MDGL Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MDGL has a market cap of 6.7B. Regarding current trading prices, VRNA is priced at $105.09, while MDGL trades at $302.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas MDGL's P/E ratio is -16.96. In terms of profitability, VRNA's ROE is -0.90%, compared to MDGL's ROE of -0.51%. Regarding short-term risk, VRNA is less volatile compared to MDGL. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check MDGL's competition here
VRNA vs RETA Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VRNA is priced at $105.09, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas RETA's P/E ratio is -66.29. In terms of profitability, VRNA's ROE is -0.90%, compared to RETA's ROE of +0.47%. Regarding short-term risk, VRNA is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check RETA's competition here
VRNA vs TGTX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, TGTX has a market cap of 5.6B. Regarding current trading prices, VRNA is priced at $105.09, while TGTX trades at $35.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas TGTX's P/E ratio is 142.00. In terms of profitability, VRNA's ROE is -0.90%, compared to TGTX's ROE of +0.19%. Regarding short-term risk, VRNA is less volatile compared to TGTX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check TGTX's competition here
VRNA vs NUVL Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, NUVL has a market cap of 5.6B. Regarding current trading prices, VRNA is priced at $105.09, while NUVL trades at $78.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas NUVL's P/E ratio is -17.73. In terms of profitability, VRNA's ROE is -0.90%, compared to NUVL's ROE of -0.31%. Regarding short-term risk, VRNA is less volatile compared to NUVL. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check NUVL's competition here
VRNA vs RYTM Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RYTM has a market cap of 5.6B. Regarding current trading prices, VRNA is priced at $105.09, while RYTM trades at $85.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas RYTM's P/E ratio is -30.44. In terms of profitability, VRNA's ROE is -0.90%, compared to RYTM's ROE of -1.80%. Regarding short-term risk, VRNA is less volatile compared to RYTM. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check RYTM's competition here
VRNA vs ABCM Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VRNA is priced at $105.09, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VRNA's ROE is -0.90%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VRNA is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check ABCM's competition here
VRNA vs ISEE Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VRNA is priced at $105.09, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VRNA's ROE is -0.90%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VRNA is less volatile compared to ISEE. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check ISEE's competition here
VRNA vs ABVX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ABVX has a market cap of 5.4B. Regarding current trading prices, VRNA is priced at $105.09, while ABVX trades at $71.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ABVX's P/E ratio is -20.68. In terms of profitability, VRNA's ROE is -0.90%, compared to ABVX's ROE of -1.06%. Regarding short-term risk, VRNA is less volatile compared to ABVX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check ABVX's competition here
VRNA vs AXSM Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, AXSM has a market cap of 5B. Regarding current trading prices, VRNA is priced at $105.09, while AXSM trades at $101.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas AXSM's P/E ratio is -17.57. In terms of profitability, VRNA's ROE is -0.90%, compared to AXSM's ROE of -3.64%. Regarding short-term risk, VRNA is less volatile compared to AXSM. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check AXSM's competition here
VRNA vs MRUS Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MRUS has a market cap of 4.9B. Regarding current trading prices, VRNA is priced at $105.09, while MRUS trades at $66.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas MRUS's P/E ratio is -15.92. In terms of profitability, VRNA's ROE is -0.90%, compared to MRUS's ROE of -0.41%. Regarding short-term risk, VRNA is less volatile compared to MRUS. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check MRUS's competition here
VRNA vs CRSP Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, VRNA is priced at $105.09, while CRSP trades at $56.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas CRSP's P/E ratio is -12.53. In terms of profitability, VRNA's ROE is -0.90%, compared to CRSP's ROE of -0.20%. Regarding short-term risk, VRNA is less volatile compared to CRSP. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check CRSP's competition here
VRNA vs TLX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, TLX has a market cap of 4.6B. Regarding current trading prices, VRNA is priced at $105.09, while TLX trades at $13.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas TLX's P/E ratio is 151.00. In terms of profitability, VRNA's ROE is -0.90%, compared to TLX's ROE of +0.06%. Regarding short-term risk, VRNA is less volatile compared to TLX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check TLX's competition here
VRNA vs SLNO Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, SLNO has a market cap of 4.6B. Regarding current trading prices, VRNA is priced at $105.09, while SLNO trades at $86.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas SLNO's P/E ratio is -18.24. In terms of profitability, VRNA's ROE is -0.90%, compared to SLNO's ROE of -0.78%. Regarding short-term risk, VRNA is less volatile compared to SLNO. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check SLNO's competition here
VRNA vs CYTK Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CYTK has a market cap of 4.5B. Regarding current trading prices, VRNA is priced at $105.09, while CYTK trades at $37.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas CYTK's P/E ratio is -7.12. In terms of profitability, VRNA's ROE is -0.90%, compared to CYTK's ROE of +8.01%. Regarding short-term risk, VRNA is less volatile compared to CYTK. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check CYTK's competition here
VRNA vs ADMA Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ADMA has a market cap of 4.5B. Regarding current trading prices, VRNA is priced at $105.09, while ADMA trades at $18.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ADMA's P/E ratio is 22.26. In terms of profitability, VRNA's ROE is -0.90%, compared to ADMA's ROE of +0.72%. Regarding short-term risk, VRNA is less volatile compared to ADMA. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check ADMA's competition here
VRNA vs ALPN Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VRNA is priced at $105.09, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VRNA's ROE is -0.90%, compared to ALPN's ROE of -0.04%. Regarding short-term risk, VRNA is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check ALPN's competition here
VRNA vs KRYS Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, KRYS has a market cap of 4.4B. Regarding current trading prices, VRNA is priced at $105.09, while KRYS trades at $153.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas KRYS's P/E ratio is 36.90. In terms of profitability, VRNA's ROE is -0.90%, compared to KRYS's ROE of +0.14%. Regarding short-term risk, VRNA is less volatile compared to KRYS. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check KRYS's competition here
VRNA vs RNA Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RNA has a market cap of 4.4B. Regarding current trading prices, VRNA is priced at $105.09, while RNA trades at $36.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas RNA's P/E ratio is -12.24. In terms of profitability, VRNA's ROE is -0.90%, compared to RNA's ROE of -0.27%. Regarding short-term risk, VRNA is less volatile compared to RNA. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check RNA's competition here
VRNA vs PCVX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, PCVX has a market cap of 4.4B. Regarding current trading prices, VRNA is priced at $105.09, while PCVX trades at $33.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas PCVX's P/E ratio is -8.51. In terms of profitability, VRNA's ROE is -0.90%, compared to PCVX's ROE of -0.17%. Regarding short-term risk, VRNA is less volatile compared to PCVX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check PCVX's competition here
VRNA vs ALKS Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ALKS has a market cap of 4.4B. Regarding current trading prices, VRNA is priced at $105.09, while ALKS trades at $26.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ALKS's P/E ratio is 12.80. In terms of profitability, VRNA's ROE is -0.90%, compared to ALKS's ROE of +0.24%. Regarding short-term risk, VRNA is less volatile compared to ALKS. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check ALKS's competition here
VRNA vs OPT Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VRNA is priced at $105.09, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas OPT's P/E ratio is -1.52. In terms of profitability, VRNA's ROE is -0.90%, compared to OPT's ROE of +2.60%. Regarding short-term risk, VRNA is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check OPT's competition here
VRNA vs ZLAB Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ZLAB has a market cap of 4.2B. Regarding current trading prices, VRNA is priced at $105.09, while ZLAB trades at $37.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ZLAB's P/E ratio is -15.12. In terms of profitability, VRNA's ROE is -0.90%, compared to ZLAB's ROE of -0.33%. Regarding short-term risk, VRNA is less volatile compared to ZLAB. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check ZLAB's competition here
VRNA vs PTCT Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, PTCT has a market cap of 4.1B. Regarding current trading prices, VRNA is priced at $105.09, while PTCT trades at $52.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas PTCT's P/E ratio is 8.00. In terms of profitability, VRNA's ROE is -0.90%, compared to PTCT's ROE of -0.72%. Regarding short-term risk, VRNA is less volatile compared to PTCT. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check PTCT's competition here
VRNA vs MRTX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VRNA is priced at $105.09, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VRNA's ROE is -0.90%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VRNA is less volatile compared to MRTX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check MRTX's competition here
VRNA vs ACAD Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ACAD has a market cap of 4B. Regarding current trading prices, VRNA is priced at $105.09, while ACAD trades at $23.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ACAD's P/E ratio is 17.39. In terms of profitability, VRNA's ROE is -0.90%, compared to ACAD's ROE of +0.35%. Regarding short-term risk, VRNA is less volatile compared to ACAD. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check ACAD's competition here
VRNA vs ACLX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ACLX has a market cap of 3.9B. Regarding current trading prices, VRNA is priced at $105.09, while ACLX trades at $71.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ACLX's P/E ratio is -23.88. In terms of profitability, VRNA's ROE is -0.90%, compared to ACLX's ROE of -0.35%. Regarding short-term risk, VRNA is less volatile compared to ACLX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check ACLX's competition here
VRNA vs AKRO Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, AKRO has a market cap of 3.9B. Regarding current trading prices, VRNA is priced at $105.09, while AKRO trades at $48.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas AKRO's P/E ratio is -13.03. In terms of profitability, VRNA's ROE is -0.90%, compared to AKRO's ROE of -0.32%. Regarding short-term risk, VRNA is less volatile compared to AKRO. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check AKRO's competition here
VRNA vs RYZB Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, VRNA is priced at $105.09, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas RYZB's P/E ratio is -57.86. In terms of profitability, VRNA's ROE is -0.90%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, VRNA is more volatile compared to RYZB. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check RYZB's competition here
VRNA vs CBAY Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, VRNA is priced at $105.09, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas CBAY's P/E ratio is -32.81. In terms of profitability, VRNA's ROE is -0.90%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, VRNA is more volatile compared to CBAY. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check CBAY's competition here
VRNA vs VKTX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, VKTX has a market cap of 3.7B. Regarding current trading prices, VRNA is priced at $105.09, while VKTX trades at $32.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas VKTX's P/E ratio is -21.15. In terms of profitability, VRNA's ROE is -0.90%, compared to VKTX's ROE of -0.20%. Regarding short-term risk, VRNA is less volatile compared to VKTX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check VKTX's competition here
VRNA vs LEGN Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, LEGN has a market cap of 3.6B. Regarding current trading prices, VRNA is priced at $105.09, while LEGN trades at $39.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas LEGN's P/E ratio is -33.11. In terms of profitability, VRNA's ROE is -0.90%, compared to LEGN's ROE of -0.20%. Regarding short-term risk, VRNA is less volatile compared to LEGN. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check LEGN's competition here
VRNA vs SWTX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, VRNA is priced at $105.09, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas SWTX's P/E ratio is -13.78. In terms of profitability, VRNA's ROE is -0.90%, compared to SWTX's ROE of -0.51%. Regarding short-term risk, VRNA is more volatile compared to SWTX. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check SWTX's competition here
VRNA vs SRRK Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, SRRK has a market cap of 3.5B. Regarding current trading prices, VRNA is priced at $105.09, while SRRK trades at $37.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas SRRK's P/E ratio is -14.53. In terms of profitability, VRNA's ROE is -0.90%, compared to SRRK's ROE of -1.18%. Regarding short-term risk, VRNA is less volatile compared to SRRK. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check SRRK's competition here
VRNA vs MTSR Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MTSR has a market cap of 3.5B. Regarding current trading prices, VRNA is priced at $105.09, while MTSR trades at $32.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas MTSR's P/E ratio is -11.26. In terms of profitability, VRNA's ROE is -0.90%, compared to MTSR's ROE of -0.63%. Regarding short-term risk, VRNA is less volatile compared to MTSR. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check MTSR's competition here
VRNA vs AAPG Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, AAPG has a market cap of 3.4B. Regarding current trading prices, VRNA is priced at $105.09, while AAPG trades at $37.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas AAPG's P/E ratio is -49.47. In terms of profitability, VRNA's ROE is -0.90%, compared to AAPG's ROE of -2.50%. Regarding short-term risk, VRNA is less volatile compared to AAPG. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check AAPG's competition here
VRNA vs PTGX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, PTGX has a market cap of 3.3B. Regarding current trading prices, VRNA is priced at $105.09, while PTGX trades at $53.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas PTGX's P/E ratio is 69.05. In terms of profitability, VRNA's ROE is -0.90%, compared to PTGX's ROE of +0.09%. Regarding short-term risk, VRNA is less volatile compared to PTGX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check PTGX's competition here
VRNA vs MLTX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MLTX has a market cap of 3.2B. Regarding current trading prices, VRNA is priced at $105.09, while MLTX trades at $50.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas MLTX's P/E ratio is -21.93. In terms of profitability, VRNA's ROE is -0.90%, compared to MLTX's ROE of -0.31%. Regarding short-term risk, VRNA is less volatile compared to MLTX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check MLTX's competition here
VRNA vs KYMR Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, KYMR has a market cap of 3.1B. Regarding current trading prices, VRNA is priced at $105.09, while KYMR trades at $43.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas KYMR's P/E ratio is -14.07. In terms of profitability, VRNA's ROE is -0.90%, compared to KYMR's ROE of -0.30%. Regarding short-term risk, VRNA is less volatile compared to KYMR. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check KYMR's competition here
VRNA vs MORF Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MORF has a market cap of 2.9B. Regarding current trading prices, VRNA is priced at $105.09, while MORF trades at $56.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas MORF's P/E ratio is -14.88. In terms of profitability, VRNA's ROE is -0.90%, compared to MORF's ROE of -0.22%. Regarding short-term risk, VRNA is more volatile compared to MORF. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check MORF's competition here
VRNA vs MOR Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MOR has a market cap of 2.9B. Regarding current trading prices, VRNA is priced at $105.09, while MOR trades at $18.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas MOR's P/E ratio is -12.64. In terms of profitability, VRNA's ROE is -0.90%, compared to MOR's ROE of -1.84%. Regarding short-term risk, VRNA is less volatile compared to MOR. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check MOR's competition here
VRNA vs APLS Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, APLS has a market cap of 2.8B. Regarding current trading prices, VRNA is priced at $105.09, while APLS trades at $22.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas APLS's P/E ratio is -12.41. In terms of profitability, VRNA's ROE is -0.90%, compared to APLS's ROE of -1.00%. Regarding short-term risk, VRNA is less volatile compared to APLS. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check APLS's competition here
VRNA vs IMVT Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, IMVT has a market cap of 2.8B. Regarding current trading prices, VRNA is priced at $105.09, while IMVT trades at $16.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas IMVT's P/E ratio is -5.89. In terms of profitability, VRNA's ROE is -0.90%, compared to IMVT's ROE of -0.81%. Regarding short-term risk, VRNA is less volatile compared to IMVT. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check IMVT's competition here
VRNA vs KDNY Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, KDNY has a market cap of 2.7B. Regarding current trading prices, VRNA is priced at $105.09, while KDNY trades at $40.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas KDNY's P/E ratio is -12.47. In terms of profitability, VRNA's ROE is -0.90%, compared to KDNY's ROE of -0.41%. Regarding short-term risk, VRNA is less volatile compared to KDNY. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check KDNY's competition here
VRNA vs CRNX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CRNX has a market cap of 2.7B. Regarding current trading prices, VRNA is priced at $105.09, while CRNX trades at $28.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas CRNX's P/E ratio is -7.52. In terms of profitability, VRNA's ROE is -0.90%, compared to CRNX's ROE of -0.31%. Regarding short-term risk, VRNA is less volatile compared to CRNX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check CRNX's competition here
VRNA vs MYOV Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MYOV has a market cap of 2.6B. Regarding current trading prices, VRNA is priced at $105.09, while MYOV trades at $26.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas MYOV's P/E ratio is -14.05. In terms of profitability, VRNA's ROE is -0.90%, compared to MYOV's ROE of +0.50%. Regarding short-term risk, VRNA is more volatile compared to MYOV. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check MYOV's competition here
VRNA vs CPRX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CPRX has a market cap of 2.6B. Regarding current trading prices, VRNA is priced at $105.09, while CPRX trades at $21.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas CPRX's P/E ratio is 13.59. In terms of profitability, VRNA's ROE is -0.90%, compared to CPRX's ROE of +0.28%. Regarding short-term risk, VRNA is less volatile compared to CPRX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check CPRX's competition here
VRNA vs RARE Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RARE has a market cap of 2.6B. Regarding current trading prices, VRNA is priced at $105.09, while RARE trades at $27.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas RARE's P/E ratio is -4.69. In terms of profitability, VRNA's ROE is -0.90%, compared to RARE's ROE of -1.86%. Regarding short-term risk, VRNA is less volatile compared to RARE. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check RARE's competition here
VRNA vs MIRM Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, MIRM has a market cap of 2.6B. Regarding current trading prices, VRNA is priced at $105.09, while MIRM trades at $51.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas MIRM's P/E ratio is -32.10. In terms of profitability, VRNA's ROE is -0.90%, compared to MIRM's ROE of -0.34%. Regarding short-term risk, VRNA is less volatile compared to MIRM. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check MIRM's competition here
VRNA vs LGND Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, LGND has a market cap of 2.5B. Regarding current trading prices, VRNA is priced at $105.09, while LGND trades at $131.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas LGND's P/E ratio is -18.05. In terms of profitability, VRNA's ROE is -0.90%, compared to LGND's ROE of -0.16%. Regarding short-term risk, VRNA is less volatile compared to LGND. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check LGND's competition here
VRNA vs RXRX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, RXRX has a market cap of 2.5B. Regarding current trading prices, VRNA is priced at $105.09, while RXRX trades at $5.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas RXRX's P/E ratio is -3.31. In terms of profitability, VRNA's ROE is -0.90%, compared to RXRX's ROE of -0.75%. Regarding short-term risk, VRNA is less volatile compared to RXRX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check RXRX's competition here
VRNA vs NAMS Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, NAMS has a market cap of 2.4B. Regarding current trading prices, VRNA is priced at $105.09, while NAMS trades at $21.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas NAMS's P/E ratio is -11.85. In terms of profitability, VRNA's ROE is -0.90%, compared to NAMS's ROE of -0.33%. Regarding short-term risk, VRNA is less volatile compared to NAMS. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check NAMS's competition here
VRNA vs PRVB Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, PRVB has a market cap of 2.4B. Regarding current trading prices, VRNA is priced at $105.09, while PRVB trades at $24.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas PRVB's P/E ratio is -16.43. In terms of profitability, VRNA's ROE is -0.90%, compared to PRVB's ROE of +1.33%. Regarding short-term risk, VRNA is more volatile compared to PRVB. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check PRVB's competition here
VRNA vs XENE Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, XENE has a market cap of 2.3B. Regarding current trading prices, VRNA is priced at $105.09, while XENE trades at $30.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas XENE's P/E ratio is -9.48. In terms of profitability, VRNA's ROE is -0.90%, compared to XENE's ROE of -0.32%. Regarding short-term risk, VRNA is less volatile compared to XENE. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check XENE's competition here
VRNA vs LBPH Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, LBPH has a market cap of 2.3B. Regarding current trading prices, VRNA is priced at $105.09, while LBPH trades at $59.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas LBPH's P/E ratio is -26.66. In terms of profitability, VRNA's ROE is -0.90%, compared to LBPH's ROE of -0.33%. Regarding short-term risk, VRNA is more volatile compared to LBPH. This indicates potentially higher risk in terms of short-term price fluctuations for VRNA.Check LBPH's competition here
VRNA vs CNTA Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CNTA has a market cap of 2.3B. Regarding current trading prices, VRNA is priced at $105.09, while CNTA trades at $17.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas CNTA's P/E ratio is -9.14. In terms of profitability, VRNA's ROE is -0.90%, compared to CNTA's ROE of -0.57%. Regarding short-term risk, VRNA is less volatile compared to CNTA. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check CNTA's competition here
VRNA vs NAMSW Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, NAMSW has a market cap of 2.3B. Regarding current trading prices, VRNA is priced at $105.09, while NAMSW trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas NAMSW's P/E ratio is N/A. In terms of profitability, VRNA's ROE is -0.90%, compared to NAMSW's ROE of -0.33%. Regarding short-term risk, VRNA is less volatile compared to NAMSW. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check NAMSW's competition here
VRNA vs APGE Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, APGE has a market cap of 2.3B. Regarding current trading prices, VRNA is priced at $105.09, while APGE trades at $38.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas APGE's P/E ratio is -10.60. In terms of profitability, VRNA's ROE is -0.90%, compared to APGE's ROE of -0.19%. Regarding short-term risk, VRNA is less volatile compared to APGE. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check APGE's competition here
VRNA vs DICE Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, DICE has a market cap of 2.3B. Regarding current trading prices, VRNA is priced at $105.09, while DICE trades at $47.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas DICE's P/E ratio is -21.91. In terms of profitability, VRNA's ROE is -0.90%, compared to DICE's ROE of +0.56%. Regarding short-term risk, VRNA is less volatile compared to DICE. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check DICE's competition here
VRNA vs IBRX Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, IBRX has a market cap of 2.2B. Regarding current trading prices, VRNA is priced at $105.09, while IBRX trades at $2.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas IBRX's P/E ratio is -4.32. In terms of profitability, VRNA's ROE is -0.90%, compared to IBRX's ROE of +0.65%. Regarding short-term risk, VRNA is less volatile compared to IBRX. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check IBRX's competition here
VRNA vs KNSA Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, KNSA has a market cap of 2.2B. Regarding current trading prices, VRNA is priced at $105.09, while KNSA trades at $30.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas KNSA's P/E ratio is 605.20. In terms of profitability, VRNA's ROE is -0.90%, compared to KNSA's ROE of +0.01%. Regarding short-term risk, VRNA is less volatile compared to KNSA. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check KNSA's competition here
VRNA vs ARWR Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, ARWR has a market cap of 2.2B. Regarding current trading prices, VRNA is priced at $105.09, while ARWR trades at $15.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas ARWR's P/E ratio is -12.74. In terms of profitability, VRNA's ROE is -0.90%, compared to ARWR's ROE of -0.46%. Regarding short-term risk, VRNA is less volatile compared to ARWR. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check ARWR's competition here
VRNA vs GLPG Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, GLPG has a market cap of 2.2B. Regarding current trading prices, VRNA is priced at $105.09, while GLPG trades at $32.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas GLPG's P/E ratio is -6.46. In terms of profitability, VRNA's ROE is -0.90%, compared to GLPG's ROE of -0.10%. Regarding short-term risk, VRNA is less volatile compared to GLPG. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check GLPG's competition here
VRNA vs AGIO Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, AGIO has a market cap of 2.2B. Regarding current trading prices, VRNA is priced at $105.09, while AGIO trades at $37.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas AGIO's P/E ratio is 3.23. In terms of profitability, VRNA's ROE is -0.90%, compared to AGIO's ROE of +0.50%. Regarding short-term risk, VRNA is less volatile compared to AGIO. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check AGIO's competition here
VRNA vs CALT Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CALT has a market cap of 2.1B. Regarding current trading prices, VRNA is priced at $105.09, while CALT trades at $40.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas CALT's P/E ratio is -22.73. In terms of profitability, VRNA's ROE is -0.90%, compared to CALT's ROE of -1.67%. Regarding short-term risk, VRNA is less volatile compared to CALT. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check CALT's competition here
VRNA vs IDYA Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, IDYA has a market cap of 2.1B. Regarding current trading prices, VRNA is priced at $105.09, while IDYA trades at $24.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas IDYA's P/E ratio is -6.67. In terms of profitability, VRNA's ROE is -0.90%, compared to IDYA's ROE of -0.29%. Regarding short-term risk, VRNA is less volatile compared to IDYA. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check IDYA's competition here
VRNA vs BLTE Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, BLTE has a market cap of 2.1B. Regarding current trading prices, VRNA is priced at $105.09, while BLTE trades at $65.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas BLTE's P/E ratio is -48.06. In terms of profitability, VRNA's ROE is -0.90%, compared to BLTE's ROE of -0.32%. Regarding short-term risk, VRNA is less volatile compared to BLTE. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check BLTE's competition here
VRNA vs IRON Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, IRON has a market cap of 2.1B. Regarding current trading prices, VRNA is priced at $105.09, while IRON trades at $59.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas IRON's P/E ratio is -15.36. In terms of profitability, VRNA's ROE is -0.90%, compared to IRON's ROE of -0.23%. Regarding short-term risk, VRNA is less volatile compared to IRON. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check IRON's competition here
VRNA vs CGON Comparison July 2025
VRNA plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VRNA stands at 8.9B. In comparison, CGON has a market cap of 2B. Regarding current trading prices, VRNA is priced at $105.09, while CGON trades at $26.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VRNA currently has a P/E ratio of -52.54, whereas CGON's P/E ratio is -17.79. In terms of profitability, VRNA's ROE is -0.90%, compared to CGON's ROE of -0.17%. Regarding short-term risk, VRNA is less volatile compared to CGON. This indicates potentially lower risk in terms of short-term price fluctuations for VRNA.Check CGON's competition here